Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in a Phase IIa clinical trial, CANFOUR, in solid tumours focusing on NSCLC and pancreatic cancer. Cantargia is also preparing to initiate a trial in the US.
In this video, the company’s chief executive officer Göran Forsberg provides an overview of R&D progress, including a summary of the recently reported interim clinical trial results and expected newsflow.